This phase III trial is evaluating a type of bladder surgery alone and in combination with immunotherapy (Pembrolizumab) in patients with muscle-invasive bladder cancer.
This trial is treating patients with muscle invasive bladder cancer.
This is a systemic therapy and surgical trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer
Commercial Sponsor
Merck
Summary
Eligible patients will be randomised to receive standard of care surgery alone OR in combination with 3 preoperative cycles of pembrolizumab and 14 cycles of postoperative pembrolizumab.
Recruiting Hospitals Read More